Post-licensure surveillance of 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged ⩾19 years old in the United States, Vaccine Adverse Event Reporting System (VAERS), June 1, 2012-December 31, 2015

The results of this study were consistent with safety data from pre-licensure studies of PCV13. We did not detect any new or unexpected AEs.